Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia
Journal of Clinical Lipidology, 06/06/2012
Ballantyne C et al. – Coadministered ERN/LRPT + simvastatin (SIM) produced marked reductions in atherogenic lipoproteins, with the greatest effect on IDL–C, and increases in protective HDL subclasses.Methods
- This double–blind study randomized.
- 1398 dyslipidemic patients equally to ERN/LRPT 1 g/20 mg, SIM (10, 20, or 40 mg), or ERN/LRPT 1 g/20 mg + SIM (10, 20, or 40 mg) once daily for 4 weeks.
- At week 5, doses were doubled, except SIM 40 mg (unchanged) and ERN/LRPT 1 g/20 mg + SIM 40 mg (switched to ERN/LRPT 2g/40 mg + SIM 40 mg).
- Cholesterol associated with lipoprotein subclasses was quantified by vertical auto profile II (VAP II).
- ERN/LRPT + SIM and SIM alone lowered LDL–C 1 and 3, whereas the effects were variable for ERN/LRPT; all three treatments increased LDL–C 4.
- ERN/LRPT + SIM and ERN/LRPT raised HDL–C 2 and 3, with greater relative percent changes in HDL 2 than HDL 3.
- ERN/LRPT + SIM for 12 weeks produced substantial reductions in IDL–C, which was additive compared with each monotherapy.